atezolizumab (Tecentriq)
atezolizumab is an FDA-licensed reference biologic from Genentech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2016
Reference approved
Reference product
Tecentriq atezolizumab
Genentech, Inc.
- Approved
- May 18, 2016
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for atezolizumab from the RCSB Protein Data Bank (PDB 5XXY).
Interactive biological assembly from PDB entry 5XXY. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for atezolizumab, in chronological order.
Reference approval
Approval date of the reference atezolizumab product.
10 yr 2 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 3 yr 7 mo
Frequently asked questions
Are there biosimilars approved for atezolizumab (Tecentriq)?
No 351(k) biosimilars or interchangeable biosimilars referencing atezolizumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.